Akari Therapeutics Plc
Akari Therapeutics Plc
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||
Cash And Cash Equivalents At Carrying Value | 3 | 0 | - | 3 | 3 | 0 | 2 | 4 | 1 | 4 | |||||
Assets Current | |||||||||||||||
Assets Current | 4 | 5 | 3 | 3 | 3 | 3 | 3 | 5 | 3 | 4 | |||||
Cash | 3 | 5 | 2 | - | 3 | 3 | 2 | - | - | - | |||||
Restricted Cash | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | |||||
Prepaid Expense Current | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | |||||
Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | 0 | |||||
Goodwill | - | 8 | 8 | 8 | 8 | 8 | - | - | - | - | |||||
Other Intangible Assets Net | 30 | 34 | 34 | 39 | 39 | 39 | - | - | - | - | |||||
Assets | 34 | 48 | 45 | 51 | 51 | 51 | 3 | 5 | 3 | 4 | |||||
Liabilities And Stockhold… | |||||||||||||||
Accounts Payable Current | 9 | 9 | 11 | 12 | 13 | 12 | 5 | 5 | 3 | 2 | |||||
Liabilities Current | |||||||||||||||
Accrued Liabilities Current | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | |||||
Liabilities Current | 13 | 12 | 16 | 17 | 21 | 20 | 9 | 9 | 6 | 5 | |||||
Convertible Debt | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | |||||
Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 1 | - | - | - | - | |||||
Other Liabilities Current | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |||||
Derivative Liabilities Noncurrent | - | 0 | 0 | - | - | - | - | - | - | - | |||||
Other Liabilities Noncurrent | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | |||||
Deferred Income Tax Liabilities Net | 6 | 7 | 7 | 8 | 8 | 8 | - | - | - | - | |||||
Liabilities | 20 | 20 | 23 | 25 | 29 | 28 | - | - | - | 5 | |||||
Common Stock Value | - | - | 7 | 7 | 6 | 5 | 2 | 2 | 2 | 1 | |||||
Additional Paid In Capital | 235 | 234 | 224 | 221 | 216 | 213 | 183 | 183 | 176 | 175 | |||||
Stockholders Equity | |||||||||||||||
Stockholders Equity | 14 | 28 | 23 | 26 | 22 | 22 | -7 | -4 | -4 | -0 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |||||
Retained Earnings Accumulated Deficit | -279 | -265 | -259 | -253 | -251 | -247 | -243 | -241 | -233 | -227 | |||||
Liabilities And Stockholders Equity | 34 | 48 | 45 | 51 | 51 | 51 | 3 | 5 | 3 | 4 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 10 | 10 | 8 | 8 | 9 | 9 | 8 | 8 | 8 | 8 | |||||
Common Stock Shares Issued | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Shares Outstanding | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 258.29% | 271.12% | - | - | - | - | - | - | - | - | - | - |
| 2025 | -8.74% | -13.33% | -25.19% | -16.68% | -6.82% | -23.70% | -34.81% | -44.23% | -54.81% | 19.83% | 277.48% | 126.03% |
| 2024 | 52.74% | 96.58% | 151.71% | -9.58% | -25.00% | -31.94% | -38.03% | -22.61% | -21.02% | 5.09% | 2.75% | -2.42% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Akari Therapeutics Plc (AKTX) — SEC Financial Statements & Analysis
Akari Therapeutics Plc (AKTX) is a pharmaceutical preparations company, incorporated in X0. Akari Therapeutics Plc trades on Nasdaq as: AKTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Akari Therapeutics Plc reported a Debt-to-Equity ratio of 1.36x, a Price-to-Book (P/B) ratio of 0.53 (TTM), at a market cap of $7.64M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 1.36x
- P/B TTM
- 0.53
- Market Cap
- $7.64M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Akari Therapeutics Plc in?
Akari Therapeutics Plc (AKTX) operates in the Pharmaceutical Preparations industry.
What is AKTX's market cap?
Akari Therapeutics Plc (AKTX) has a market capitalization of $7.64M as of 2026-03-31.
What exchange does AKTX trade on?
Akari Therapeutics Plc (AKTX) trades on the Nasdaq.
Where is Akari Therapeutics Plc incorporated?
Akari Therapeutics Plc is incorporated in United Kingdom.